

November 28, 2012



## Griffin Securities Initiates Research Coverage on Oragenics

TAMPA, Fla.-- Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) ([www.oragenics.com](http://www.oragenics.com)) today announced that [Griffin Securities, Inc.](#) has initiated research coverage on the company with a BUY rating and a 12-month target price of \$5.00 per share. For more information, please see the full initiation report [here](#).

### About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names [Evora](#) and [ProBiora](#) in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.

For more information, visit [www.oragenics.com](http://www.oragenics.com). Follow Oragenics on [Facebook](#) and [Twitter](#).

**Safe Harbor Statement:** *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

Oragenics, Inc.

**Corporate Contact:**

**Michael Sullivan**, 813-286-7900 x246

**CFO**

Direct: 813-786-6431

[msullivan@oragenics.com](mailto:msullivan@oragenics.com)

or

**Investor Contact:**

**Robert Giordano**, 1-800-625-2236 x7770

**President**

Direct: 917-327-3938

[rgiordanonyc@gmail.com](mailto:rgiordanonyc@gmail.com)

Source: Oragenics, Inc.